• Call
  • Email
  • Branches
  • SMS
Broking
: 1800 300 29999 (Toll free) Dial 1 for Call N Trade (8:30am-11:30pm, Mon-Fri & 10am-2pm, Sat)
MyUniverse
:: 022-6180 2828
(10am-7pm, Mon-Sat)
Get to a branch closest to you
 ABML Branches
 ABML & ABMML Branches
 ABMML Retail
 ABMML Wealth Management
To reach us for any of our services, SMS the below short codes to 567679
  1. Broking/Distribution SMS: ABM to 567679
  2. Wealth Management SMS: ABMM to 567679
  3. Corporate & Treasury SMS: SOLUTIONS to 567679
  4. Real Estate Advisory SMS: PROPERTY to 567679
  5. Channel Partner SMS: CP to 567679
  6. Franchisee Partner: ABM to 567679
  7. Portfolio Management Services: ABMCS 567679
Share with us your valuable feedback
SENSEX 27976.52-118.82 -0.42%
NIFTY 8590.65-45.00 -0.52%
SENSEX 27976.52-118.82 -0.42% NIFTY 8590.65-45.00 -0.52%
Market Today
Company LTP() Prev. Close() Change() Change(%)
Axis Bank 553.65 538.30 15.35 2.85
Power Grid Corpn 171.40 168.65 2.75 1.63
Tata Steel 367.65 363.80 3.85 1.06
Wipro 546.85 542.40 4.45 0.82
Infosys 1,088.80 1,080.50 8.30 0.77
NTPC 158.00 157.15 0.85 0.54
Index Charts
  • Sensex
  • NIfty
News
Jul 26 , 2016 15:18
The result was announced during market hours today, 26 July 2016.

Meanwhile, the BSE Sensex was down 139.41 points, or 0.5%, to 27,955.93.

On BSE, so far 1.32 lakh shares were traded in the counter, compared with an average volume of 31,000 shares in the past two weeks. The stock hit a high of Rs 3,516.95 and a low of Rs 3,305.15 so far during the day.

Dr Reddy's Laboratories' (DRL) consolidated net profit fell 76.28% to Rs 153.50 crore on 14.06% decline in total income to Rs 3289.50 crore in Q1 June 2016 over Q1 June 2015.

DRL's Co-chairman and CEO, GV Prasad said that the company has come through a difficult first quarter, with its top and bottom lines impacted by a decline in volume growth, particularly in the US market and the loss of business in Venezuela. DRL also faced a number of challenges in the quarter including price erosion and delayed launches as a result of the warning letter, which significantly impacted its earnings, Prasad said. However, the company continues to take actions that focus on remediation, strengthening its quality systems and executing on its strong product pipeline, Prasad said. DRL remains focused on generating long term, sustainable growth, he added.

Dr Reddy's Laboratories is an integrated global pharmaceutical company. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr Reddy's offers a portfolio of products and services including active pharmaceutical ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Powered by Capital Market - Live News

 Full Story
Corporate Actions
Company Name Date Purpose
ABC Bearings 27-Jul-16 ABC Bearings Ltd has informed BSE that a Me..
ADF Foods 27-Jul-16 Adf Foods Ltd has informed BSE that the mee..
Agro Tech Foods. 27-Jul-16 Agro Tech Foods Ltd has informed BSE that a..
Ashoka Refinerie 27-Jul-16 Ashoka Refineries Ltd has informed BSE that..
Asian Paints 27-Jul-16 Asian Paints Ltd has informed BSE that a me..
Market Barometer
Name Close Price() Volume Weight In Index(%)
Tata Consultancy Ser.. 2,548.30 502,124.15 10.57
Reliance Industries .. 1,023.30 331,826.82 6.98
HDFC Bank Ltd 1,238.70 314,016.89 6.61
ITC Ltd 251.55 303,871.68 6.40
Infosys Ltd 1,088.80 250,091.34 5.26
Housing Development .. 1,367.60 216,361.44 4.55
Products
ATTENTION INVESTORS :
Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Prevent Unauthorized Transactions in your Demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from NSDL / CDSL on the same day......................issued in the interest of investors. "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.    No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorize your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

Securities Broking is through Aditya Birla Money Limited; NSE - SEBI Registration No.: Equity/ Debt - INB 23 1347031, Derivatives – INF 23 1347031, Currency – INE 23 1347031; BSE-SEBI Registration No.: Equity/ Debt - INB 01 1347037, Derivatives - INF 01 1347037, Currency- Exchange Registered; MSEI - SEBI Registration No.: Equity – INB 26 1347034 and Derivative – INF 26 1347034, Currency - INE 26 1347031; USE - SEBI Registration No.: Currency – INE 27 1347036. NSDL /CDSL : IN-DP-17-2015. Commodity Broking is through Aditya Birla Commodities Broking Limited; NCDEX Membership No.: 00158; MCX Membership No.28730; FMC Registration No.: NCDEX / TCM / CORP / 0180; MCX / TCM / CORP / 0023. National Spot Exchange Membership No : 12590. Mutual Fund Distribution is through Aditya Birla Money Mart Limited, ARN 0003. Life Insurance is through Aditya Birla Money Insurance Advisory Services Limited, licensed to act as a Corporate Agent of Birla Sun Life Insurance Company Limited. IRDA license no. BSL 308007. The services of myuniverse.co.in are offered by Aditya Birla Customer Services Limited. Currently as a Member, we are not engaged in proprietary trading.

Copyright © 2014. Aditya Birla Money Limited All Rights Reserved. Developed and Powered by C-MOTS Infotech (ISO 9001:2008 certified)